Which has better valuation and earnings, KRYS or PGEN?

Krystal Biotech has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 24.86 $204.83M $7.98 40.95 Precigen $85.72M 31.40 -$250.64M -$1.04 N/A

Is KRYS or PGEN more profitable?

Krystal Biotech has a net margin of 54.82% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Krystal Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Precigen -183.98% 423.75% 84.39%

Does the media refer more to KRYS or PGEN?

In the previous week, Precigen had 7 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for Precigen and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.23 beat Precigen's score of 0.42 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, KYMR or PGEN?

Precigen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 224.74 -$311.35M -$3.24 N/A Precigen $85.72M 31.40 -$250.64M -$1.04 N/A

Does the media refer more to KYMR or PGEN?

In the previous week, Precigen had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Precigen and 6 mentions for Kymera Therapeutics. Precigen's average media sentiment score of 0.42 beat Kymera Therapeutics' score of 0.29 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARWR or PGEN?

In the previous week, Precigen had 5 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 8 mentions for Precigen and 3 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.42 beat Precigen's score of 0.42 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PGEN or PTGX?

In the previous week, Precigen had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Precigen and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.62 beat Precigen's score of 0.42 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IBRX or PGEN?

Precigen has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 90.65 -$351.40M -$0.97 N/A Precigen $85.72M 31.40 -$250.64M -$1.04 N/A

Is IBRX or PGEN more profitable?

Precigen has a net margin of -183.98% compared to ImmunityBio's net margin of -598.55%. Precigen's return on equity of 423.75% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Precigen -183.98% 423.75% 84.39%

Does the media favor IBRX or PGEN?

In the previous week, ImmunityBio had 2 more articles in the media than Precigen. MarketBeat recorded 10 mentions for ImmunityBio and 8 mentions for Precigen. ImmunityBio's average media sentiment score of 0.52 beat Precigen's score of 0.42 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Precigen (PGEN) Competitors

$7.55 -0.19 (-2.45%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$7.57 +0.02 (+0.28%)

As of 10/6/2026 07:47 PM Eastern

Compare

PGEN vs. KRYS, KYMR, ARWR, PTGX, and IBRX

Should you buy Precigen stock or one of its competitors? Precigen's main competitors and comparable companies include Krystal Biotech (KRYS), Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Precigen compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Krystal Biotech has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.86	$204.83M	$7.98	40.95
Precigen	$85.72M	31.40	-$250.64M	-$1.04	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Precigen has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Precigen	-183.98%	423.75%	84.39%

In the previous week, Precigen had 7 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for Precigen and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.23 beat Precigen's score of 0.42 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech presently has a consensus price target of $377.20, indicating a potential upside of 15.42%. Precigen has a consensus price target of $13.67, indicating a potential upside of 81.02%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats Precigen on 10 of the 17 factors compared between the two stocks.

How does Precigen compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Precigen has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

33.5% of Precigen shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kymera Therapeutics currently has a consensus target price of $134.46, suggesting a potential upside of 26.87%. Precigen has a consensus target price of $13.67, suggesting a potential upside of 81.02%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Precigen has a net margin of -183.98% compared to Kymera Therapeutics' net margin of -285.33%. Precigen's return on equity of 423.75% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Precigen	-183.98%	423.75%	84.39%

In the previous week, Precigen had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Precigen and 6 mentions for Kymera Therapeutics. Precigen's average media sentiment score of 0.42 beat Kymera Therapeutics' score of 0.29 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precigen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	224.74	-$311.35M	-$3.24	N/A
Precigen	$85.72M	31.40	-$250.64M	-$1.04	N/A

Summary

Precigen beats Kymera Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Precigen compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Arrowhead Pharmaceuticals has higher revenue and earnings than Precigen. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$669.50M	12.95	-$1.63M	-$2.25	N/A
Precigen	$85.72M	31.40	-$250.64M	-$1.04	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Precigen	-183.98%	423.75%	84.39%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals presently has a consensus price target of $98.31, indicating a potential upside of 59.75%. Precigen has a consensus price target of $13.67, indicating a potential upside of 81.02%. Given Precigen's stronger consensus rating and higher probable upside, analysts clearly believe Precigen is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Arrowhead Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Precigen has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, Precigen had 5 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 8 mentions for Precigen and 3 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.42 beat Precigen's score of 0.42 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Precigen beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Precigen compare to Protagonist Therapeutics?

Precigen (NASDAQ:PGEN) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Protagonist Therapeutics has a net margin of 29.40% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Precigen has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Precigen currently has a consensus price target of $13.67, indicating a potential upside of 81.02%. Protagonist Therapeutics has a consensus price target of $147.13, indicating a potential upside of 6.09%. Given Precigen's higher probable upside, equities research analysts plainly believe Precigen is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Protagonist Therapeutics has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$85.72M	31.40	-$250.64M	-$1.04	N/A
Protagonist Therapeutics	$46.02M	195.02	-$130.15M	$1.03	134.65

In the previous week, Precigen had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Precigen and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.62 beat Precigen's score of 0.42 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.5% of Precigen shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Precigen on 10 of the 17 factors compared between the two stocks.

How does Precigen compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 46.54%. Precigen has a consensus price target of $13.67, indicating a potential upside of 81.02%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Precigen has a net margin of -183.98% compared to ImmunityBio's net margin of -598.55%. Precigen's return on equity of 423.75% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Precigen	-183.98%	423.75%	84.39%

Precigen has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	90.65	-$351.40M	-$0.97	N/A
Precigen	$85.72M	31.40	-$250.64M	-$1.04	N/A

ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Precigen has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 2 more articles in the media than Precigen. MarketBeat recorded 10 mentions for ImmunityBio and 8 mentions for Precigen. ImmunityBio's average media sentiment score of 0.52 beat Precigen's score of 0.42 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmunityBio and Precigen tied by winning 8 of the 16 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.76B	$3.88B	$7.19B	$13.39B
Dividend Yield	N/A	3.65%	2.53%	17.38%
P/E Ratio	-7.26	13.22	273.36	26.36
Price / Sales	31.40	1,239.06	592.19	95.90
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	125.83	16.67	11.04	6.33
Net Income	-$250.64M	-$22.65M	$3.50B	$381.96M
7 Day Performance	-11.80%	-4.10%	-2.07%	-0.40%
1 Month Performance	6.34%	-12.08%	-7.06%	-4.84%
1 Year Performance	128.10%	13.63%	5.77%	1.42%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	3.6746 of 5 stars	$7.55 -2.5%	$13.67 +81.0%	+140.4%	$2.76B	$85.72M	N/A	47
KRYS Krystal Biotech	4.4621 of 5 stars	$337.08 -2.5%	$377.20 +11.9%	+81.0%	$10.24B	$389.13M	42.24	295	Positive News
KYMR Kymera Therapeutics	2.1799 of 5 stars	$112.00 +0.0%	$133.21 +18.9%	+84.2%	$9.31B	$39.21M	N/A	273	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.772 of 5 stars	$65.46 -0.7%	$98.31 +50.2%	+64.1%	$9.29B	$829.45M	N/A	711
PTGX Protagonist Therapeutics	1.7958 of 5 stars	$142.44 +0.4%	$147.13 +3.3%	+116.2%	$9.18B	$46.02M	138.29	141

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors

PGEN vs. KRYS, KYMR, ARWR, PTGX, and IBRX

How does Precigen compare to Krystal Biotech?

Summary

How does Precigen compare to Kymera Therapeutics?

Summary

How does Precigen compare to Arrowhead Pharmaceuticals?

Summary

How does Precigen compare to Protagonist Therapeutics?

Summary

How does Precigen compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precigen (PGEN) Competitors

PGEN vs. KRYS, KYMR, ARWR, PTGX, and IBRX

How does Precigen compare to Krystal Biotech?

Which has better valuation and earnings, KRYS or PGEN?

Do insiders & institutionals believe in KRYS or PGEN?

Which has more risk and volatility, KRYS or PGEN?

Is KRYS or PGEN more profitable?

Does the media refer more to KRYS or PGEN?

Do analysts prefer KRYS or PGEN?

Summary

How does Precigen compare to Kymera Therapeutics?

Which has more risk & volatility, KYMR or PGEN?

Do institutionals & insiders hold more shares of KYMR or PGEN?

Do analysts prefer KYMR or PGEN?

Is KYMR or PGEN more profitable?

Does the media refer more to KYMR or PGEN?

Which has preferable valuation and earnings, KYMR or PGEN?

Summary

How does Precigen compare to Arrowhead Pharmaceuticals?

Which has preferable valuation & earnings, ARWR or PGEN?

Is ARWR or PGEN more profitable?

Do insiders & institutionals have more ownership in ARWR or PGEN?

Do analysts rate ARWR or PGEN?

Which has more volatility & risk, ARWR or PGEN?

Does the media refer more to ARWR or PGEN?

Summary

How does Precigen compare to Protagonist Therapeutics?

Is PGEN or PTGX more profitable?

Which has more risk & volatility, PGEN or PTGX?

Do analysts rate PGEN or PTGX?

Which has higher earnings and valuation, PGEN or PTGX?

Does the media prefer PGEN or PTGX?

Do insiders & institutionals have more ownership in PGEN or PTGX?

Summary

How does Precigen compare to ImmunityBio?

Do analysts rate IBRX or PGEN?

Is IBRX or PGEN more profitable?

Which has better valuation & earnings, IBRX or PGEN?

Which has more volatility and risk, IBRX or PGEN?

Do institutionals & insiders have more ownership in IBRX or PGEN?

Does the media favor IBRX or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools